World-class sites, reliable enrollment, and high performance for clinical trials across Europe
Velocity opened its first European site in Hamburg , Germany, in mid-2022, and expanded that same year with a site Leipzig, followed by two more sites in the U.K. with the acquisition of Egin Research. In 2023, Velocity added three greenfield sites in the U.K., six sites in Poland, and four more in Germany (via acquisitions of KO-MED Centra Kliniczne, ClinMedica Research, InterMed, Klinische Forschung Berlin, The Pulmonary Research Institute at the LungenClinic Großhansdorf, and KLB Gesundheitsforschung Lübeck).
The acquisition of KO-MED, Poland’s leading site network, marked Velocity’s entrance into oncology research. The acquisition of The Pulmonary Research Institute in Germany further demonstrated Velocity’s commitment to supporting specialty research programs across Europe and worldwide.